Advertisements


We are Sorry, This Page doesn't Exist


The Daily Biotech Pulse: Epizyme"s Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) read more.....»»

Category: blogSource: benzingaFeb 14th, 2020

2019 Review: Top Hedge Fund Stocks vs. Arena Pharmaceuticals, Inc. (ARNA)

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an invest.....»»

Category: topSource: insidermonkeyJan 8th, 2020

Merck, Eisai receive FDA priority review for KEYTRUDA plus LENVIMA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 6th, 2021

Arena Pharma"s Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain

Arena Pharmaceuticals Inc (NASDAQ: ARNA) has read more.....»»

Category: blogSource: benzingaMar 3rd, 2021

Pfizer"s 20-Valent Pneumococcal Vaccine Application Accepted EU Review

read more.....»»

Category: blogSource: benzingaFeb 26th, 2021

Pfizer"s application for TicoVac accepted by FDA for priority review

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 23rd, 2021

Sesen Bio"s Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike

read more.....»»

Category: blogSource: benzingaFeb 16th, 2021

Arena Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ARNA

Market News Video.....»»

Category: topSource: redinewsMay 13th, 2020

Bristol-Myers" application for AML candidate accepted by FDA for priority review

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 1st, 2020

The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs .....»»

Category: earningsSource: benzingaMar 5th, 2020

The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) read more.....»»

Category: blogSource: benzingaMar 5th, 2020

Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results

SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for th.....»»

Category: earningsSource: benzingaFeb 26th, 2020

Eisai to pull weight-loss drug due to cancer concerns

Eisai Co. Ltd. said Thursday that it would pull its weight-loss drug Belviq off the market in the U.S. A long-term trial,.....»»

Category: topSource: marketwatchFeb 14th, 2020

Eisai to voluntarily withdraw Belviq, Belviq XR in U.S.

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 13th, 2020

Harvard Medical School researchers allege ‘erosion’ of standards at FDA, criticizing shorter drug-review times

‘The FDA has increasingly accepted less data and more surrogate measures, and has shortened its review times,’ according to a new study in JAMA......»»

Category: topSource: marketwatchJan 17th, 2020

Harvard Medical School researchers allege ‘erosion’ of standards at FDA — criticizes shorter drug-review times

‘The FDA has increasingly accepted less data and more surrogate measures, and has shortened its review times,’ according to a new study in JAMA......»»

Category: topSource: marketwatchJan 16th, 2020

Harvard Medical School researchers allege ‘erosion of evidence standards’ at FDA

The FDA has increasingly accepted less data and shortened its review times for drugs, according to a new study in JAMA......»»

Category: topSource: marketwatchJan 15th, 2020

The Daily Biotech Pulse: Canadian Approval For Amarin"s Vascepa, Innate Pharma"s Blood Cancer Drug Accepted For Review In Europe

The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 31.) 0 read more.....»»

Category: blogSource: benzingaJan 2nd, 2020

Bradley Center demo, Grand Avenue remake among nation"s images of 2019: Year in Review

State-of-the-art buildings went up (e.g., sports arena: Chase Center in San Francisco). Established properties came down (e.g., sports arena: Bradley Center in Milwaukee). The year 2019 also brought us new corporate headquarters and re-imagined lo.....»»

Category: topSource: bizjournalsDec 31st, 2019

2019 Year in Review: Restaurant empire sold, arena renovations approved and a pro sports team"s new owner

Restaurants, retail, the airport and sports had their share of big, breaking stories in 2019 that included a new owner, bankruptcy and a grocery chain buying a lot of land......»»

Category: topSource: bizjournalsDec 19th, 2019